Format

Send to

Choose Destination
J Alzheimers Dis. 2018;61(1):169-183. doi: 10.3233/JAD-170128.

Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.

Author information

1
CSIRO Health and Biosecurity/Australian e-Health Research Centre, Brisbane, QLD, Australia.
2
Cooperative Research Centre for Mental Health, Parkville, VIC, Australia.
3
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.
4
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.
5
National Dementia Diagnostics Laboratory, The University of Melbourne, VIC, Australia.
6
Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia.
7
Department of Anaesthesia and Perioperative Pain Medicine, Centre for Anaesthesia and Cognitive Function, St Vincent's Hospital, Melbourne, Australia.
8
Academic Unit for Psychiatry of Old Age, The University of Melbourne, Melbourne, Australia.
9
ADx NeuroSciences, Gent, Belgium.
10
Department of Medicine (RMH), The University of Melbourne, Parkville, Australia.

Abstract

BACKGROUND:

To enhance the accuracy of clinical diagnosis for Alzheimer's disease (AD), pre-mortem biomarkers have become increasingly important for diagnosis and for participant recruitment in disease-specific treatment trials. Cerebrospinal fluid (CSF) biomarkers provide a low-cost alternative to positron emission tomography (PET) imaging for in vivo quantification of different AD pathological hallmarks in the brains of affected subjects; however, consensus around the best platform, most informative biomarker and correlations across different methodologies are controversial.

OBJECTIVE:

Assessing levels of Aβ-amyloid and tau species determined using three different versions of immunoassays, the current study explored the ability of CSF biomarkers to predict PET Aβ-amyloid (32 Aβ-amyloid-and 45 Aβ-amyloid+), as well as concordance between CSF biomarker levels and PET Aβ-amyloid imaging.

METHODS:

Prediction and concordance analyses were performed using a sub-cohort of 77 individuals (48 healthy controls, 15 with mild cognitive impairment, and 14 with AD) from the Australian Imaging Biomarker and Lifestyle study of aging.

RESULTS:

Across all three platforms, the T-tau/Aβ42 ratio biomarker had modestly higher correlation with SUVR/BeCKeT (ρ= 0.69-0.8) as compared with Aβ42 alone (ρ= 0.66-0.75). Differences in CSF biomarker levels between the PET Aβ-amyloid-and Aβ-amyloid+ groups were strongest for the Aβ42/Aβ40 and T-tau/Aβ42 ratios (p < 0.0001); however, comparison of predictive models for PET Aβ-amyloid showed no difference between Aβ42 alone and the T-tau/Aβ42 ratio.

CONCLUSION:

This study confirms strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.

KEYWORDS:

Amyloid; PET; biomarker; cerebrospinal fluid; concordance

PMID:
29171991
DOI:
10.3233/JAD-170128
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center